Compare ADMA Biologics Inc (ADMA) vs Uranium Energy Corp (UEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Uranium Energy Corp — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Uranium Energy Corp trades at $9.79 (market cap $4.90B). The key difference: Uranium Energy Corp is far larger — about 2.3× ADMA Biologics Inc's market cap, and Uranium Energy Corp is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | UEC | |
|---|---|---|
Market Cap | $2.13B | $4.90B |
Sector | Health | Energy |
52-Week High | $20.38 | $20.14 |
52-Week Low | $7.60 | $5.92 |
Enterprise Value | $2.20B | $4.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
UEC trades at $10.57, down 2.22% today, amid bearish technical signals and weak quarterly results. The stock shows negative profitability with a -513.24% net income margin and has missed earnings expectations in two of the last three quarters. However, analyst sentiment remains strongly positive with 87.5% buy ratings, supported by the company's strategic positioning in uranium production and substantial liquidity of $794 million with no debt.
The outlook is mixed: strong analyst support and nuclear sector tailwinds offer long-term potential, but near-term risks include persistent losses, high valuation multiples, and operational execution challenges. Investors should weigh the company's asset base and market position against its current financial performance and cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
